[1] Wang H, Men P, Xiao Y,et al.Hepatitis B infection in the general population of China: a systematic review and meta-analysis.BMC Infect Dis,2019,19:811-814. [2] 盛秋菊,韩超,丁洋,等.慢性乙型肝炎抗病毒治疗与疾病长期预后-慢性乙型肝炎防治指南(2019年版)更新要点解读. 中国实用内科杂志, 2020,40:7-11. [3] 刘志红,零小樟,江建宁.慢性乙型肝炎抗病毒治疗终点标志物研究进展.中国实用内科杂志,2020,40:451-456. [4] 梁携儿,孙剑.如何评价ALT水平与疾病进展及治疗时机的关系.中华肝脏病杂志, 2020, 28:992-994. [5] 中华医学会感染病学分会,中华医学会肝病学分会.慢性乙型肝炎防治指南(2019年版). 国际流行病学传染病学杂志, 2019, 46:423-446. [6] 纪林秀, 杨兴祥. ALT水平正常或轻度升高慢性乙型肝炎的肝组织学改变及临床特征分析. 临床肝胆病杂志, 2020, 36:778-782. [7] Agbim U, Asrani SK. Non-invasive assessment of liver fibrosis and prognosis: an update on serum and elastography markers. Expert Rev Gastroenterol Hepatol, 2019,13:361-374. [8] Liu Y, Gao LF, Liang XH, et al. Role of Tim-3 in hepatitis B virus infection: An overview.World J Gastroenterol,2016,22:2294-2303. [9] 金蕾,李旭,叶珺,等. FIB-4对HBeAg阴性慢性HBV感染者抗病毒治疗指征中肝脏炎症和纤维化的判断价值.安徽医科大学学报, 2020,55:146-150. [10] 李贲,程丹颖,纪世博,等.慢性乙型肝炎抗病毒治疗10年预后及其影响因素. 胃肠病学和肝病学杂志, 2020, 29:84-87. [11] 杨东亮.丙氨酸转氨酶复常在乙型肝炎抗病毒治疗中的价值. 中华肝脏病杂志, 2019, 27:741-747. [12] 朱萍,路毓峰,王丽,等.慢性乙型肝炎患者肝纤维化血清标志物与肝组织炎症分级的关系.河北医药,2019,41:2497-2500. [13] Kim MN, Lee JH, Chon YE,et al.Fibrosis-4, aspartate transaminase-to-platelet ratio index, and gamma-glutamyl transpeptidase-to-platelet ratio for risk assessment of hepatocellular carcinoma in chronic hepatitis B patients: comparison with liver biopsy.Eur J Gastroenterol Hepatol,2020,32:433-439. [14] 龚航, 李良平. FibroScan分别与GPR,APRI,NFS,FIB-4联合应用对慢性乙型肝炎合并非酒精性脂肪性肝病进展期肝纤维化的诊断价值比较. 临床肝胆病杂志, 2020, 36:63-67. [15] 汤珊,梅婷婷,柳雅立,等.乙型肝炎相关显著肝纤维化无创预测指标及模型的研究.北京医学, 2019, 41:509-511,515. [16] Gefen T, Castro I, Muharemagic D, et al. A TIM-3 Oligonucleotide Aptamer Enhances T Cell Functions and Potentiates Tumor Immunity in Mice. Mol Ther, 2017, 25:456-461. [17] 雷云洁.血清可溶性Tim-3的表达对肝硬化的诊断及疾病严重程度的相关研究. 昆明:昆明医科大学,2019. |